ABOUT US

Our Story

Infinome’s founding team members have spent their careers pioneering technologies and strategies to accelerate the engineering of biology in order to make the development of new biobased manufacturing processes faster and more cost-effective. Our team helped revolutionize commercial enzyme engineering, resulting in a more robust, efficient, and rapid process for optimizing industrial enzyme performance. We were inspired to apply these powerful forward engineering strategies to metabolic pathways and whole genomes, however, the tools needed to efficiently edit these larger sequence spaces did not yet exist. As early members of Inscripta, our team attacked this problem and were instrumental in the development the groundbreaking Onyx™ platform and its application to forward engineering. During that time we identified further unmet needs we could address by leveraging the Inscripta platform into a complete genome engineering technology stack. This led to the hatching of Infinome, which is separately pursuing significant opportunities in the bioeconomy by harnessing a poweful confluence of technologies and strategies to fully capitalize on the infinite potential of the genome and usher in the next (bio) industrial revolution.

Our Approach

Historically, the complexity of biology has made it difficult to engineer — despite staggering investments in the commercialization of bioproducts, progress has proven to be frustratingly slow, expensive, and laborious. Because we still don’t understand biology enough to design systems from anything like first principles, there remains a profound need for better engineering tools and strategies. We asked a few questions:
  • Instead of tinkering here and there with a few genes at a time, why not explore the entire genome?
  • What if we applied reliable principles of rapid enzyme engineering to whole genomes?
  • Inspired by Nature’s evolutionary processes, what if we could apply those principles to forward engineer biology with untold precision, efficiency, and speed?
In our view, in order to be successful, we needed an integrated suite of technologies and processes that work together in concert. The efficiency and throughput of every step in the engineering cycle is critical as mismatches often result in high overall costs and long delays. Our novel GenoScaler™ platform unifies, for the first time, all the essential components needed to carry out rapid, genome scale engineering: Massively parallel CRISPR genome editing; fast and affordable strain library construction; machine learning; smart automation & analytics; predictive fermentation; and software & informatics — all guided by the principles of directed evolution and executed by small, agile, highly efficient teams. The result is a Lean Bioengineering™ operation that delivers commercial bioproducts at a fraction of the time and cost never before possible.

About Infinome

Our goal is to replace unsustainable processes and products with cleaner, more cost-effective solutions and create a more sustainable planet for everyone. Infinome is now actively developing the GenoScaler™ platform to enable rapid engineering of genomes for internal and external, partner-related, opportunities. We operate as an independent subsidiary of Inscripta.

Our Process

WHAT

HOW

Our Partners

Technology
leaders in

WHO WANT
TO ACHIEVE

FROM

Technology Leaders In

WHO WANT TO ACHIEVE

FROM

OUR Team

More
Info

Richard Fox PhD

CEO, CTO, & CO-FOUNDER

More
Info

Mike Clay PhD

COO & CO-FOUNDER

More
Info

Andrew Garst PhD

CIO & CO-FOUNDER

More
Info

Dan Held PhD

CSO & CO-FOUNDER

r-fox

MORE INFO

Richard Fox, PhD

CEO, CTO, & CO-FOUNDER

m-clay

MORE INFO

Mike Clay, PhD

COO & CO-FOUNDER

andrew-g

MORE INFO

Andrew Garst, PhD

CIO & CO-FOUNDER

d-held

MORE INFO

Dan Held, PhD

CSO & CO-FOUNDER

Strengths

Strengths